Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717112 | 0.93 | KDM4E (0.47) | LMNAMAPTPOLBPABPC1EIF4H | |
| SCHEMBL10187707 | 0.80 | MEN1 (0.44) | LMNAMAPTKDM4ETP53NPC1 | |
| SCHEMBL2093339 | 0.80 | MAPT (0.45) | LMNAMAPTPOLBTP53MAPK1 | |
| SCHEMBL2092485 | 0.80 | TRPV1 (0.43) | LMNAKDM4ETP53NPC1RAB9A | |
| SCHEMBL3764187 | 0.79 | CRACR2A (0.53) | LMNANPC1RAB9AMAPK1 | |
| SCHEMBL2092464 | 0.78 | AKT1 (0.46) | MAPTTP53 | |
| SCHEMBL10187725 | 0.77 | RAB9A (0.47) | MAPTTP53NPC1RAB9AALDH1A1 | |
| SCHEMBL2093694 | 0.76 | CRACR2A (0.47) | LMNAMAPTTP53NPC1RAB9A | |
| SCHEMBL2093287 | 0.76 | RAB9A (0.48) | LMNAKDM4ETP53NPC1RAB9A | |
| SCHEMBL2096498 | 0.76 | CRACR2A (0.47) | LMNAMAPTTP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | claimed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1809294-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | claimed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7709518-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2004626-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1809294-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | LMNA 3912/4885MAPT 1930/4885POLB 4854/4885 |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | LMNA 1685/4885MAPT 1416/4885POLB 4276/4885 |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | CXCR2, CXCL8, CCR9 | LMNA 1685/4885MAPT 1416/4885POLB 4276/4885 |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | LMNA 1685/4885MAPT 1416/4885POLB 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.